![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Senate Bill Seeks to Speed Fast-Track Options for Opioid Alternatives
Senate Bill Seeks to Speed Fast-Track Options for Opioid Alternatives
April 18, 2018
In the latest addition to the swirl of opioid-related bills circulating on Capitol Hill, four senators introduced legislation to require the FDA to issue guidance on how breakthrough and accelerated approval designations apply to novel, non-opioid or non-addictive pain medications.
The approval process for breakthrough therapy and accelerated approval designations is unclear for opioids and addiction treatments, according to the bill’s sponsors — Sens. Orrin Hatch (R-Utah), Joe Donnelly (D-Ind.), Todd Young (R-Ind.), and Michael Bennet (D-Colo.).
Hatch said the bill would cut red tape to ensure manufacturers of non-opioid pain medications can bring them to market as quickly as possible.
Upcoming Events
-
21Oct